Incidence of aspirin resistance is higher in patients with acute coronary syndrome and atrial fibrillation than without atrial fibrillation


Baş H., Aksoy F., Bağcı A., Varol E., Altınbaş A.

REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, vol.66, no.6, pp.800-805, 2020 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 66 Issue: 6
  • Publication Date: 2020
  • Doi Number: 10.1590/1806-9282.66.6.800
  • Journal Name: REVISTA DA ASSOCIACAO MEDICA BRASILEIRA
  • Journal Indexes: Science Citation Index Expanded, Scopus, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, Directory of Open Access Journals
  • Page Numbers: pp.800-805
  • Keywords: Aspirin, Clopidogrel, Drug resistance, Acute coronary syndrome, Atrial fibrillation, C-REACTIVE PROTEIN, ANTITHROMBOTIC THERAPY, PERCUTANEOUS CORONARY, MYOCARDIAL-INFARCTION, ANTICOAGULATION, MANAGEMENT, INTERVENTION, INFLAMMATION, CLOPIDOGREL, STRATEGIES

Abstract

In patients with atrial fibrillation, standard anticoagulation with a vitamin K antagonist plus dual antiplatelet therapy with a P2Y12 inhibitor and aspirin is the standard of care after percutaneous coronary intervention (PCI). While this therapy reduces the risk of thrombosis and stroke, it increases the risk of bleeding. It is unclear whether the antiplatelet effect of aspirin and clopidogrel may worsen atrial fibrillation (AF).